BG61383B1 - Pharmacetical preparations - Google Patents

Pharmacetical preparations Download PDF

Info

Publication number
BG61383B1
BG61383B1 BG97644A BG9764493A BG61383B1 BG 61383 B1 BG61383 B1 BG 61383B1 BG 97644 A BG97644 A BG 97644A BG 9764493 A BG9764493 A BG 9764493A BG 61383 B1 BG61383 B1 BG 61383B1
Authority
BG
Bulgaria
Prior art keywords
pharmaceutically active
active substance
fatty acid
pharmaceutical preparation
preparation according
Prior art date
Application number
BG97644A
Other languages
Bulgarian (bg)
English (en)
Other versions
BG97644A (bg
Inventor
Stephen G Barnwell
Original Assignee
Cortecs Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortecs Ltd filed Critical Cortecs Ltd
Publication of BG97644A publication Critical patent/BG97644A/bg
Publication of BG61383B1 publication Critical patent/BG61383B1/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Laminated Bodies (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
BG97644A 1990-10-19 1993-04-16 Pharmacetical preparations BG61383B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909022788A GB9022788D0 (en) 1990-10-19 1990-10-19 Pharmaceutical formulations
PCT/GB1991/001824 WO1992006680A1 (en) 1990-10-19 1991-10-18 Biphasic release formulations for lipophilic drugs

Publications (2)

Publication Number Publication Date
BG97644A BG97644A (bg) 1994-04-29
BG61383B1 true BG61383B1 (en) 1997-07-31

Family

ID=10684032

Family Applications (1)

Application Number Title Priority Date Filing Date
BG97644A BG61383B1 (en) 1990-10-19 1993-04-16 Pharmacetical preparations

Country Status (21)

Country Link
US (1) US5391377A (xx)
EP (1) EP0553178B1 (xx)
JP (1) JP3276368B2 (xx)
KR (1) KR100188642B1 (xx)
AT (1) ATE122881T1 (xx)
AU (1) AU656924B2 (xx)
BG (1) BG61383B1 (xx)
CA (1) CA2093206C (xx)
CZ (1) CZ282822B6 (xx)
DE (1) DE69110052T2 (xx)
DK (1) DK0553178T3 (xx)
ES (1) ES2073177T3 (xx)
FI (1) FI104408B (xx)
GB (1) GB9022788D0 (xx)
HK (1) HK85296A (xx)
HU (2) HUT64215A (xx)
NO (1) NO305505B1 (xx)
RO (1) RO114739B1 (xx)
RU (1) RU2121344C1 (xx)
SK (1) SK279845B6 (xx)
WO (1) WO1992006680A1 (xx)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
GB9325445D0 (en) * 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5567592A (en) * 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
DE4443175A1 (de) * 1994-12-05 1996-06-13 Jenapharm Gmbh Neue pulsatile Arzneiform
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
WO1996024332A1 (en) * 1995-02-06 1996-08-15 Nanosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5665386A (en) * 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
JPH11507356A (ja) * 1995-06-07 1999-06-29 アブマックス，インコーポレイティド 経口薬理化合物の生物有用性を高めるためのエッセンシャルオイルの利用
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6024980A (en) * 1996-06-28 2000-02-15 Mcneil-Ppc, Inc. Multiphase soft gelatin dosage form
ES2322405T3 (es) * 1996-07-08 2009-06-19 Penwest Pharmaceuticals Co. Matriz de liberacion controlada para farmacos insolubles en dosis elevadas.
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US20030008919A1 (en) * 1999-06-03 2003-01-09 Jean-Baptiste Roullet Use of retinoids to treat high blood pressure and other cardiovascular disease
JP2002500190A (ja) 1998-01-08 2002-01-08 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 海洋海綿から誘導されるキネシンモーターモジュレーター
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6200968B1 (en) * 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
FR2782006B1 (fr) * 1998-08-07 2002-04-19 Gattefosse Ets Sa Composition a liberation prolongee apte a former une micro-emulsion
AU775523B2 (en) 1998-12-11 2004-08-05 Pharmasolutions, Inc. Self-emulsifying compositions for drugs poorly soluble in water
US6057289A (en) * 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
EP1280533A2 (en) * 2000-05-11 2003-02-05 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1492511B3 (fr) * 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040077621A1 (en) * 2002-08-08 2004-04-22 Academia Sinica Antioxidants
CA2515544A1 (en) * 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
AU2005204391A1 (en) * 2004-01-14 2005-07-28 Lavipharm Laboratories, Inc. Transdermal delivery device for dihydropyridine type calcium antagonists containing at least one fatty acid
AU2005212005A1 (en) * 2004-02-11 2005-08-25 Athpharma Limited Chronotherapeutic compositions and methods of their use
JP4980211B2 (ja) 2004-05-12 2012-07-18 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 細胞単離方法
WO2006095347A2 (en) 2005-03-10 2006-09-14 Ben Gurion University Of The Negev Research And Development Authority Ltd. VOLTAGE DEPENDENT ANION CHANNEL (VDACl) COMPOSITIONS AND METHODS OF USE THEREOF FOR REGULATING APOPTOSIS
US8648045B2 (en) 2005-03-10 2014-02-11 Ben Gurion University Of The Negev Research And Development Authority Ltd. VDAC1 compositions and methods of use thereof for regulating apoptosis
EA012440B1 (ru) 2005-04-29 2009-10-30 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Пептид, композиция на его основе для лечения патологий, связанных c воспалительными процессами
EP2407484B1 (en) 2005-06-24 2016-06-22 The Walter And Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
CA2637350A1 (en) 2006-01-20 2007-07-26 Child Health Research Institute Inc Method of treatment, prophylaxis and diagnosis of pathologies of the bone
US8440788B2 (en) * 2006-04-06 2013-05-14 Ben-Gurion University Of The Negev Research And Development Authority Ltd. N-terminal VDAC variants and uses thereof
WO2007123153A1 (ja) * 2006-04-19 2007-11-01 Ono Pharmaceutical Co., Ltd. 経口投与用カプセル
MY153288A (en) * 2006-06-28 2015-01-29 Hovid Berhad An effective pharmaceutical carrier for poorly bioavailable drugs
KR101390695B1 (ko) * 2006-08-01 2014-04-30 오츠카 세이야쿠 가부시키가이샤 약리 활성 물질의 흡수성이 개선된 의약 조성물
AU2007309408A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica N.V. Dry granulated pharmaceutical compositions and methods for producing same
US8252897B2 (en) * 2007-06-21 2012-08-28 Angelica Therapeutics, Inc. Modified toxins
CN101835490A (zh) 2007-08-02 2010-09-15 阿雷斯托生物科学股份有限公司 Lox和loxl2抑制剂及其应用
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
DK2195331T3 (da) * 2007-08-28 2014-02-03 Uab Research Foundation Syntetiske polypeptider, der efterligner apolipoprotein e, og anvendelsesmetoder
PT2205245E (pt) * 2007-10-03 2015-10-13 Wista Lab Ltd Utilização terapêutica de diaminofenotiazinas
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
EP2276445B1 (en) * 2008-05-12 2012-07-04 Capsugel Belgium NV Improved capsule with air-vents
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
CN102711809B (zh) 2009-08-17 2015-09-30 特雷康制药公司 使用抗-内皮因子抗体和抗-vegf剂联合治疗癌症
ES2363965B1 (es) * 2009-11-20 2013-01-24 Gp Pharm S.A. Cápsulas de principios activos betabloqueantes y ésteres de ácidos grasos poliinsaturados.
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US9249189B2 (en) 2010-01-18 2016-02-02 Albany Medical College Alpha-fetoprotein “ring and tail” peptides
ES2739505T3 (es) 2010-08-27 2020-01-31 Gilead Biologics Inc Anticuerpos contra la metaloproteinasa 9 de la matriz
WO2012051567A2 (en) 2010-10-15 2012-04-19 The Trustees Of Columbia University In The City Of New York Obesity-related genes and their proteins and uses thereof
CA2834657A1 (en) 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
JP6368645B2 (ja) 2011-09-29 2018-08-01 ピーエルエックス オプコ インコーポレーテッド 胃腸管に沿った医薬の標的化放出のためのｐＨ依存性担体、それによる組成物、ならびにこれらの製造および使用
WO2013130078A1 (en) 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
EP3255063A3 (en) 2012-02-29 2018-02-07 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
WO2013128453A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
TW201406707A (zh) 2012-05-04 2014-02-16 Acucela Inc 用以治療糖尿病性視網膜病變及其他眼部疾病之方法
US10441636B2 (en) 2012-07-20 2019-10-15 La Trobe University Method of diagnosis and treatment
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
JP6570511B2 (ja) 2013-03-14 2019-09-04 ユーエイビー リサーチ ファンデーション アポリポタンパク質模倣体及びその使用
WO2014144708A1 (en) 2013-03-15 2014-09-18 The Regents Of The University Of California Peptides having reduced toxicity that stimulate cholesterol efflux
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
DK2968503T3 (en) 2013-03-15 2018-12-03 Intrinsic Lifesciences Llc ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF
US9758559B2 (en) 2013-07-25 2017-09-12 B.G. Negev Technologies And Applications Ltd., At Ben-Gurion University Short peptides derived from VDAC1, compositions and methods of use thereof
CN105873944A (zh) 2013-12-20 2016-08-17 耶路撒冷希伯来大学伊森姆研究发展有限公司 促血管发生的肽和肽缀合物
TW201544511A (zh) 2014-02-27 2015-12-01 Gilead Sciences Inc 針對基質金屬蛋白酶９之抗體及其使用方法
CA2951535A1 (en) 2014-06-11 2015-12-17 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
US10793614B2 (en) 2014-07-17 2020-10-06 Yissum Research Development Company of the Hebrew University ofJerusaIem Ltd. Antagonists of fish reproduction
EP3169700A1 (en) 2014-07-17 2017-05-24 Yissum Research Development Company of The Hebrew University of Jerusalem Ltd. Antagonists of neurokinin b in fish reproduction
JP7081923B2 (ja) 2014-07-31 2022-06-07 ユーエイビー リサーチ ファンデーション アポｅ模倣ペプチド及び血漿コレステロールを取り除くためのより高い効果
US20160074473A1 (en) 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
JP2017537084A (ja) 2014-11-12 2017-12-14 トラコン ファーマシューティカルズ、インコーポレイテッド 抗エンドグリン抗体及びその用途
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CN108884135B (zh) 2015-10-27 2024-03-26 昆士兰大学 治疗方法以及可用于其中的药剂
WO2017083700A1 (en) 2015-11-13 2017-05-18 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
US20170174788A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
US20170306050A1 (en) 2016-04-08 2017-10-26 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
WO2018071814A1 (en) 2016-10-14 2018-04-19 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
AU2018212937A1 (en) 2017-01-30 2019-08-15 Hudson Institute of Medical Research A method of treatment
WO2018213803A1 (en) 2017-05-19 2018-11-22 Neon Therapeutics, Inc. Immunogenic neoantigen identification
KR102344616B1 (ko) 2017-05-30 2021-12-31 더 보드 오브 리젠츠 오브 더 유니버시티 오브 오클라호마 항-더블코르틴-유사 키나제 1 항체 및 사용 방법
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
GB2603044A (en) 2019-06-11 2022-07-27 Myeloid Therapeutics Inc Macrophage specific engager compositions and methods of use thereof
KR20220062488A (ko) 2019-06-12 2022-05-17 바이오엔테크 유에스 인크. 신생항원 조성물 및 이의 용도
AU2021244695A1 (en) 2020-03-26 2022-11-10 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
CA3189285A1 (en) 2020-08-13 2022-02-17 Vikram JUNEJA T cell manufacturing compositions and methods
WO2022098905A2 (en) 2020-11-04 2022-05-12 Myeloid Therapeutics, Inc. Engineered chimeric fusion protein compositions and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1600639A (en) * 1978-05-23 1981-10-21 Kali Chemie Pharma Gmbh Medicament preparation having resorption properties and method of producing the same
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4946870A (en) * 1986-06-06 1990-08-07 Union Carbide Chemicals And Plastics Company Inc. Delivery systems for pharmaceutical or therapeutic actives
IT1200178B (it) * 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
US5229422A (en) * 1987-09-07 1993-07-20 Teijin Limited Extemporaneous preparation type kit of a pharmaceutical substance-containing fat emulsion
EP0351897A3 (en) * 1988-06-17 1990-03-21 The Procter & Gamble Company Skin penetration system for salts of amine-functional drugs
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
GB8909022D0 (en) * 1989-04-20 1989-06-07 Cortecs Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
SK279845B6 (sk) 1999-04-13
DK0553178T3 (da) 1995-07-24
WO1992006680A1 (en) 1992-04-30
BG97644A (bg) 1994-04-29
JP3276368B2 (ja) 2002-04-22
AU8731591A (en) 1992-05-20
KR100188642B1 (ko) 1999-06-01
FI104408B (fi) 2000-01-31
HUT64215A (en) 1993-12-28
JPH06502143A (ja) 1994-03-10
DE69110052T2 (de) 1995-10-05
ATE122881T1 (de) 1995-06-15
HU9301121D0 (en) 1993-07-28
CA2093206C (en) 2002-01-29
FI931745A (fi) 1993-04-16
NO931410L (no) 1993-04-16
GB9022788D0 (en) 1990-12-05
DE69110052D1 (de) 1995-06-29
FI931745A0 (fi) 1993-04-16
EP0553178A1 (en) 1993-08-04
CA2093206A1 (en) 1992-04-20
ES2073177T3 (es) 1995-08-01
HU211617A9 (en) 1995-12-28
CZ282822B6 (cs) 1997-10-15
HK85296A (en) 1996-05-24
EP0553178B1 (en) 1995-05-24
KR930701989A (ko) 1993-09-08
US5391377A (en) 1995-02-21
CZ64193A3 (en) 1994-01-19
SK36393A3 (en) 1993-07-07
RO114739B1 (ro) 1999-07-30
AU656924B2 (en) 1995-02-23
RU2121344C1 (ru) 1998-11-10
NO305505B1 (no) 1999-06-14
NO931410D0 (no) 1993-04-16

Similar Documents

Publication Publication Date Title
BG61383B1 (en) Pharmacetical preparations
US11911398B2 (en) Treating Vitamin D insufficiency and deficiency with 25-hydroxyvitamin D2 and 25-hydroxyvitamin D3
US5433951A (en) Sustained release formulation containing captopril and method
EP2279729B1 (en) Controlled release preparations
CA2309836C (en) Drug delivery systems utilizing liquid crystal structures
ES2326783T3 (es) Composiciones de n-benzoilestaurosporina espontaneamente dispersables.
JP6537980B2 (ja) 脂質化合物、トリグリセリドおよび界面活性剤を含む組成物、ならびにその使用方法
WO2003055466A1 (en) Microemulsion preconcentrate
JP2005508938A (ja) プロミセル薬学的組成物
EP3047847A1 (en) Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
JP4656483B2 (ja) 新規な自己乳化薬物送達システム
JP2012502065A (ja) 弱イオン性化合物の剤形
HRP980378A2 (en) Encapsulated solution dosage forms of sertraline
EP4098246A1 (en) Formulation of nintedanib
CZ464299A3 (cs) Želatinové zapouzdření roztokové dávkovači formy sertralinu